Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome.
Kusunoki J, Kanatani A, Moller DE. Kusunoki J, et al. Endocrine. 2006 Feb;29(1):91-100. doi: 10.1385/ENDO:29:1:91. Endocrine. 2006. PMID: 16622296 Review.
A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production.
Chung CC, Ohwaki K, Schneeweis JE, Stec E, Varnerin JP, Goudreau PN, Chang A, Cassaday J, Yang L, Yamakawa T, Kornienko O, Hodder P, Inglese J, Ferrer M, Strulovici B, Kusunoki J, Tota MR, Takagi T. Chung CC, et al. Among authors: kusunoki j. Assay Drug Dev Technol. 2008 Jun;6(3):361-74. doi: 10.1089/adt.2007.105. Assay Drug Dev Technol. 2008. PMID: 18452391
Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
Harada N, Oda Z, Hara Y, Fujinami K, Okawa M, Ohbuchi K, Yonemoto M, Ikeda Y, Ohwaki K, Aragane K, Tamai Y, Kusunoki J. Harada N, et al. Among authors: kusunoki j. Mol Cell Biol. 2007 Mar;27(5):1881-8. doi: 10.1128/MCB.01122-06. Epub 2007 Jan 8. Mol Cell Biol. 2007. PMID: 17210641 Free PMC article.
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, Previs S, Milstein S, Fitzgerald K, Kelley DE, Horton JD. Kim CW, et al. Among authors: kusunoki j. Cell Metab. 2017 Aug 1;26(2):394-406.e6. doi: 10.1016/j.cmet.2017.07.009. Cell Metab. 2017. PMID: 28768177 Free PMC article.
ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus [corrected].
Castle JC, Hara Y, Raymond CK, Garrett-Engele P, Ohwaki K, Kan Z, Kusunoki J, Johnson JM. Castle JC, et al. Among authors: kusunoki j. PLoS One. 2009;4(2):e4369. doi: 10.1371/journal.pone.0004369. Epub 2009 Feb 3. PLoS One. 2009. PMID: 19190759 Free PMC article.
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, Previs S, Milstein S, Fitzgerald K, Kelley DE, Horton JD. Kim CW, et al. Among authors: kusunoki j. Cell Metab. 2017 Sep 5;26(3):576. doi: 10.1016/j.cmet.2017.08.011. Cell Metab. 2017. PMID: 28877461 No abstract available.
Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion.
Aragane K, Kusunoki J, Kitamine T, Yamaura T, Ohnishi H. Aragane K, et al. Among authors: kusunoki j. Jpn J Pharmacol. 1998 Mar;76(3):309-12. doi: 10.1254/jjp.76.309. Jpn J Pharmacol. 1998. PMID: 9593225
Postprandial hyperlipidemia in Zucker diabetic fatty fa/fa rats, an animal model of type II diabetes, and its amelioration by acyl-CoA:cholesterol acyltransferase inhibition.
Fujinami K, Kojima K, Aragane K, Kusunoki J. Fujinami K, et al. Among authors: kusunoki j. Jpn J Pharmacol. 2001 May;86(1):127-9. doi: 10.1254/jjp.86.127. Jpn J Pharmacol. 2001. PMID: 11430465
Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation.
Rong JX, Kusunoki J, Oelkers P, Sturley SL, Fisher EA. Rong JX, et al. Among authors: kusunoki j. Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):122-7. doi: 10.1161/01.ATV.0000148202.49842.3b. Epub 2004 Oct 21. Arterioscler Thromb Vasc Biol. 2005. PMID: 15499046
Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Chiwata T, Aragane K, Fujinami K, Kojima K, Ishibashi S, Yamada N, Kusunoki J. Chiwata T, et al. Among authors: kusunoki j. Br J Pharmacol. 2001 Aug;133(7):1005-12. doi: 10.1038/sj.bjp.0704160. Br J Pharmacol. 2001. PMID: 11487509 Free PMC article.
Feedback